2616 Stock Overview
A biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
CStone Pharmaceuticals Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.13 |
| 52 Week High | HK$4.18 |
| 52 Week Low | HK$0.97 |
| Beta | 0.20 |
| 11 Month Change | -27.56% |
| 3 Month Change | -47.69% |
| 1 Year Change | -72.10% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -91.17% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2616 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -31.5% | 8.5% | 10.9% |
| 1Y | -72.1% | -7.9% | 13.4% |
Return vs Industry: 2616 underperformed the Hong Kong Biotechs industry which returned -42.3% over the past year.
Return vs Market: 2616 underperformed the Hong Kong Market which returned -15.9% over the past year.
Price Volatility
| 2616 volatility | |
|---|---|
| 2616 Average Weekly Movement | 12.7% |
| Biotechs Industry Average Movement | 7.4% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in HK Market | 13.7% |
| 10% least volatile stocks in HK Market | 3.5% |
Stable Share Price: 2616's share price has been volatile over the past 3 months.
Volatility Over Time: 2616's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 474 | Jason Yang | www.cstonepharma.com |
CStone Pharmaceuticals, a biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally. It offers Sugemalimab, a monoclonal antibody against programmed death (PD) ligand 1; GAVRETO, an RET inhibitor for the treatment of patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor to treat adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation. The company’s product pipeline includes Nofazinlimab, a PD-1 antibody for the treatment of patients with hepatocellular carcinoma; and Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor to treat adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation.
CStone Pharmaceuticals Fundamentals Summary
| 2616 fundamental statistics | |
|---|---|
| Market cap | HK$1.44b |
| Earnings (TTM) | -HK$815.54m |
| Revenue (TTM) | HK$522.88m |
2.6x
P/S Ratio-1.7x
P/E RatioIs 2616 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2616 income statement (TTM) | |
|---|---|
| Revenue | CN¥481.07m |
| Cost of Revenue | CN¥218.30m |
| Gross Profit | CN¥262.77m |
| Other Expenses | CN¥1.01b |
| Earnings | -CN¥750.33m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.59 |
| Gross Margin | 54.62% |
| Net Profit Margin | -155.97% |
| Debt/Equity Ratio | 28.7% |
How did 2616 perform over the long term?
See historical performance and comparison